BACKGROUND: Leiomyoma, one of the most common benign tumors, causes morbidity during the reproductive years in women. The molecular pathogenesis of the disease is not clear. Leiomyomas are hormone-sensitive tumors affecting around 20%-25% of women. Gene polymorphism studies could be important and explaining in the evaluation of multifactorial diseases such as leiomyoma. Polymorphisms involving genes responsible for the synthesis and signalization of steroid hormones could be used as genetic markers for hormone-related conditions. The purpose of this study was to analyze the effect of ERα-351 XbaI A/G, ERα-397 PvuII T/C, and progesterone receptor (PGR) PROGINS polymorphisms on the development of leiomyomas. MATERIAL AND METHODS: In this study, 213 samples (103 leiomyoma patients and 110 healthy controls) participated. The ERα-351 XbaI A/G and ERα-397 PvuII T/C gene polymorphisms were analyzed using PCR-RFLP method. PGR PROGINS polymorphism was analyzed by PCR method with specific primers. RESULTS: The genotype distribution and allele frequency of the ERα-351 XbaI A/G, ERα-397 PvuII T/C, and PGR PROGINS polymorphisms were not statistically different between leiomyoma patient and control groups (p > 0.05). CONCLUSION: This study reflects that ERα and PGR PROGINS polymorphisms may not be one of the many genetic factors for leiomyoma susceptibility.
BACKGROUND:Leiomyoma, one of the most common benign tumors, causes morbidity during the reproductive years in women. The molecular pathogenesis of the disease is not clear. Leiomyomas are hormone-sensitive tumors affecting around 20%-25% of women. Gene polymorphism studies could be important and explaining in the evaluation of multifactorial diseases such as leiomyoma. Polymorphisms involving genes responsible for the synthesis and signalization of steroid hormones could be used as genetic markers for hormone-related conditions. The purpose of this study was to analyze the effect of ERα-351 XbaI A/G, ERα-397 PvuII T/C, and progesterone receptor (PGR) PROGINS polymorphisms on the development of leiomyomas. MATERIAL AND METHODS: In this study, 213 samples (103 leiomyomapatients and 110 healthy controls) participated. The ERα-351 XbaI A/G and ERα-397 PvuII T/C gene polymorphisms were analyzed using PCR-RFLP method. PGR PROGINS polymorphism was analyzed by PCR method with specific primers. RESULTS: The genotype distribution and allele frequency of the ERα-351 XbaI A/G, ERα-397 PvuII T/C, and PGR PROGINS polymorphisms were not statistically different between leiomyomapatient and control groups (p > 0.05). CONCLUSION: This study reflects that ERα and PGR PROGINS polymorphisms may not be one of the many genetic factors for leiomyoma susceptibility.
Authors: A M Dunning; C S Healey; P D Pharoah; M D Teare; B A Ponder; D F Easton Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-10 Impact factor: 4.254
Authors: S M Rowe; S J Coughlan; N J McKenna; E Garrett; D G Kieback; D N Carney; D R Headon Journal: Cancer Res Date: 1995-07-01 Impact factor: 12.701
Authors: M S Rein; W L Powell; F C Walters; S Weremowicz; R M Cantor; R L Barbieri; C C Morton Journal: Mol Hum Reprod Date: 1998-01 Impact factor: 4.025
Authors: L M Marshall; D Spiegelman; R L Barbieri; M B Goldman; J E Manson; G A Colditz; W C Willett; D J Hunter Journal: Obstet Gynecol Date: 1997-12 Impact factor: 7.661
Authors: Francesco Massart; Lucia Becherini; Francesca Marini; Ivo Noci; Luigi Piciocchi; Francesca Del Monte; Laura Masi; Alberto Falchetti; Annalisa Tanini; Gianfranco Scarselli; Luisa Brandi Journal: Med Sci Monit Date: 2003-01